Mikhail Zibinsky

Mikhail Zibinsky is an experienced professional in the field of chemistry and drug discovery, currently serving as Director and Principal Investigator at RAPT Therapeutics since April 2015. Notable achievements include the discovery of RPT193, a CCR4 antagonist for inflammation, and FLX475, also a CCR4 antagonist targeting cancer, both currently in phase II clinical trials. Prior experience includes a scientist role at Flexus Biosciences, where BMS986205 (FLX287), an IDO1 inhibitor for cancer, was discovered. Mikhail's earlier positions include senior postdoctoral researcher at UC Berkeley, research associate at The Scripps Research Institute, and research assistant at the University of Southern California. Mikhail holds a Ph.D. in Chemistry from the University of Southern California and a B.S. in Computer Science and Chemistry from St. Petersburg State University.